Learn More

Insights

Social Equity and Interstate Competition: Maryland Cannabis Regulation Under Scrutiny in Federal Court

By Meg Nash, Bridgette Nikisher
Jan 31, 2024

A recent lawsuit filed against the Maryland Cannabis Administration (MCA) threatens to delay the highly anticipated cannabis business license lottery. The lawsuit alleges that the MCA's social equity licensing program unfairly favors Maryland residents, potentially violating the Dormant Commerce Clause of the U.S. Constitution. This blog post explains the specifics of the lawsuit, its potential impact on the licensing process, and the broader legal questions surrounding residency requirements in cannabis licensing.

The DEA’s Scheduling of Marijuana: What Happens After the DEA Publishes Its Rule?

By Jason Adelstone
Jan 30, 2024

On August 29, 2023, the Department of Health and Human Services (“HHS”) sent the Drug Enforcement Administration (“DEA”) its recommendation to move marijuana from Schedule I to Schedule III of the Controlled Substances Act (“CSA”). Since then, the marijuana industry has waited in suspense for the DEA to make the final call as to what schedule marijuana will be placed. Read this Insights post that outlines the complex process of marijuana rescheduling in the US and outlines the key steps involved, from rule publication to review and final rule, emphasizing the critical role of stakeholder engagement in securing a Schedule III classification.

Colorado Natural Medicine Advisory Bulletin #7: December 2023

By Joshua Kappel, Jeff Fitzgerald, Psychedelic Alpha
Jan 18, 2024

Colorado Natural Medicine Advisory Bulletins provide updates on the implementation of Colorado's legal psychedelics program, the Natural Medicine Health Act. Bulletin #7 focuses on updates from the recent subcommittee meetings.